ORDERDYNAMICS
OrderDynamics , developers of the world’s most advanced, out-of-the-box Distributed Order Management (DOM) System, today announced new research findings. The Omni-2000 Research: Global sheds light on the omni-channel service offerings of more than 2,000 retailers worldwide. This report is a follow-up and expansion of the company’s 2017 Omni-1000 Research .
Key findings include that less than half of retailers provide shoppers with access to basic inventory visibility. Out of the 2,000+ retailers, only a shocking 38.1% show basic inventory visibility on product pages. A strict like-for-like, year-over-year comparison found a 30.7% drop in active online inventory visibility. This is a concerning drop in an industry experiencing so much change. Passive inventory visibility is a factor in this drop. Unlike active inventory visibility, a passive approach only signals when a good is out of stock.
Based on data collected from retailers in a variety of sectors across the U.S., U.K., Canada, Australia, France, Germany and Austria, the report revealed:
- 37.6% of retailers offer click & collect today.
- 34.8% of BOPIS retailers commit to having orders ready within 24 hours.
- 72.6% of omni-channel retailers offer BORIS (Buy Online, Return In-Store).
- 11.4% of omni-channel merchants have a site optimized for mobile commerce.
For the second year in a row, the U.K. is the leading country in click & collect, with 64% of retailers offering the service. Consistent with last year’s Omni-1000 results, the U.S. lags, ranking lowest of the countries assessed, with only 27.5% of retailers providing BOPIS. Over 69% of consumers acknowledge having tried omni-channel retailing and would like to see more of it. As such, retailers are missing an opportunity for promotion. Further, only 57.1% of retailers offering the service advertise it on their website’s front page.
“To increase sales and retain customers, omni-channel retailers today need to provide customers with clarity,” said Nick McLean, CEO, OrderDynamics. “The Omni-2000 reveals where retailers are strong, and other areas where they are lacking across a variety of metrics. Whether it is low stock visibility or general service awareness about cross-channel fulfillment, these are opportunities to get closer to what drives customer demand. OrderDynamics hopes retailers can use these benchmarks to improve their own businesses.”
Click here to access the global study.
About OrderDynamics
OrderDynamics is the world’s leading Out-of-the-Box Distributed Order Management Technology provider. Focused on powering retail fulfillment, OrderDynamics helps clients make omni-channel retail a reality. Its DOM provides client capabilities like order orchestration, enterprise-wide inventory visibility, returns management, customer service, and store driven fulfillment. OrderDynamics enables customer options like Buy Online Pickup In-Store (BOPIS), and ship-from-store, creating exceptional shopping experiences. Iconic brands like Speedo, Boardriders, Columbia Sportswear, JYSK, Princess Auto, Crabtree and Evelyn, and Browns Shoes use OrderDynamics technology across North America, Europe, Asia and Australia. For more information, visit http://www.orderdynamics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005187/en/
Contact:
Ketner Group Communications (for OrderDynamics) Amanda Reed, 512-794-8876 amanda@ketnergroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom